Israel Biotech Fund

Vensica Medical develops an ultrasound-based drug delivery system for treating urinary bladder cancer. Its device improves drug uptake and penetration into the bladder wall, aiming to enhance treatment efficiency and reduce recurrence rates.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

Vensica Medical develops an ultrasound-based drug delivery system for treating urinary bladder cancer. Its device improves drug uptake and penetration into the bladder wall, aiming to enhance treatment efficiency and reduce recurrence rates.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

BioSight Ltd., established in 1999 and headquartered in Lod, Israel, is a biopharmaceutical company specializing in the development of innovative cancer-targeted pro-drugs. It focuses on creating non-toxic conjugates like its cytarabine-asparagine conjugate for treating acute myeloid leukemia patients worldwide. BioSight's proprietary technology, S2DOT™, enables targeted drug release inside cancer cells, minimizing systemic toxicity compared to conventional chemotherapy treatments.

BioSight Ltd., established in 1999 and headquartered in Lod, Israel, is a biopharmaceutical company specializing in the development of innovative cancer-targeted pro-drugs. It focuses on creating non-toxic conjugates like its cytarabine-asparagine conjugate for treating acute myeloid leukemia patients worldwide. BioSight's proprietary technology, S2DOT™, enables targeted drug release inside cancer cells, minimizing systemic toxicity compared to conventional chemotherapy treatments.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing small-molecule therapeutics for patients with rare and aggressive cancers, using a bioinformatics platform and next-generation sequencing to identify tumorigenic drivers and guide targeted therapies. The company is developing AL101, an intravenous gamma secretase inhibitor for Notch-activating tumors such as adenoid cystic carcinoma, which is in Phase II, and AL102, an oral gamma secretase inhibitor for desmoid tumors, in Phase I. Ayala has a collaboration with Novartis to advance AL102 for multiple myeloma. Founded in 2017, the company is headquartered in Rehovot, Israel.

Biond Biologics is a biotechnology company specializing in drug discovery and development. Established in 2016, it focuses on immuno-oncology drugs for cancer treatment and autoimmune diseases, along with a novel platform enabling antibody-targeting of intracellular immune factors.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing small-molecule therapeutics for patients with rare and aggressive cancers, using a bioinformatics platform and next-generation sequencing to identify tumorigenic drivers and guide targeted therapies. The company is developing AL101, an intravenous gamma secretase inhibitor for Notch-activating tumors such as adenoid cystic carcinoma, which is in Phase II, and AL102, an oral gamma secretase inhibitor for desmoid tumors, in Phase I. Ayala has a collaboration with Novartis to advance AL102 for multiple myeloma. Founded in 2017, the company is headquartered in Rehovot, Israel.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Pharma Two B develops clinically differentiated pharmaceutical products based on approved drugs. It specializes in fixed-dose combinations of two or more drugs, focusing on Parkinson's disease and cancer treatments. The company aims to enhance current treatment options by providing high clinical value and shorter regulatory pathways.

Vidac Pharma Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel, focused on developing innovative therapies for oncologic and dermatologic diseases. The company is dedicated to discovering first-in-class medicines that address significant unmet medical needs, particularly in the areas of skin cancer and solid tumors. Vidac's lead product, VDA-1102, is an ointment currently in clinical development for treating actinic keratosis and cutaneous T-cell lymphoma. Additionally, the company is developing a second molecule, VDA-1275, which may have applications across various solid tumors. Vidac Pharma's unique approach targets the VDAC/HK2 system, which is specific to malignant cells, facilitating selective apoptosis of cancer cells while sparing healthy tissue, thus aiming to deliver effective and well-tolerated treatments.